Drug-resistant tuberculosis: Response to More . (2017).
作者信息
Basu Saurav
机构信息
Department of Community Medicine, Maulana Azad Medical College, New Delhi, India.
出版信息
J Family Med Prim Care. 2017 Oct-Dec;6(4):887-888. doi: 10.4103/jfmpc.jfmpc_309_17.
Abstract
摘要
相似文献
1
Drug-resistant tuberculosis: Response to More . (2017).耐多药结核病：对更多……的反应。（2017年）
J Family Med Prim Care. 2017 Oct-Dec;6(4):887-888. doi: 10.4103/jfmpc.jfmpc_309_17.
2
Murine Mycobacterium marinum Infection as a Model for Tuberculosis.鼠源海分枝杆菌感染作为结核病模型
Methods Mol Biol. 2017;1535:301-315. doi: 10.1007/978-1-4939-6673-8_20.
3
Molecular snapshot of Mycobacterium tuberculosis population structure and drug-resistance in Kyrgyzstan.分子快照显示了吉尔吉斯斯坦结核分枝杆菌种群结构和耐药性。
Tuberculosis (Edinb). 2013 Sep;93(5):501-7. doi: 10.1016/j.tube.2013.05.008. Epub 2013 Jul 24.
4
Burden of Multidrug Resistant Mycobacterium tuberculosis Among New Cases in Al-Madinah Al-Monawarah, Saudi Arabia.沙特阿拉伯麦地那市新发病例中耐多药结核分枝杆菌的负担
Infect Disord Drug Targets. 2017;17(1):14-23. doi: 10.2174/1871526517666161116104242.
5
Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".对杜基等人《全基因组测序指导耐多药结核病治疗方案选择》一文的回复
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00616-18. Print 2018 Aug.
6
For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance.谁的丧钟为谁敲响：异烟肼预防治疗与结核病耐药性。
Sci Transl Med. 2013 Apr 10;5(180):180fs12. doi: 10.1126/scitranslmed.3006094.
7
8
Mutations in rpoB gene of rifampicin resistant clinical isolates of Mycobacterium tuberculosis in Japan.
Kansenshogaku Zasshi. 1995 Apr;69(4):413-9. doi: 10.11150/kansenshogakuzasshi1970.69.413.
9
Corrigendum: Daru et al., Decentralized, Community-Based Treatment for Drug-Resistant Tuberculosis: Bangladesh Program Experience.勘误：达鲁等人，《基于社区的耐药结核病分散式治疗：孟加拉国项目经验》。
Glob Health Sci Pract. 2018 Dec 27;6(4):766. doi: 10.9745/GHSP-D-18-00398.
10
Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".对安东尼等人《保护吡嗪酰胺：改善耐多药结核病治疗效果的优先事项》一文的回复
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00427-17. Print 2017 Jun.
本文引用的文献
1
Profile of drug-resistant tuberculosis in Western Maharashtra.马哈拉施特拉邦西部的耐药结核病概况。
J Family Med Prim Care. 2017 Jan-Mar;6(1):29-33. doi: 10.4103/2249-4863.214954.
2
Patients pathways to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study from a south Indian district.在一个碎片化卫生系统中患者的结核病诊断与治疗路径：来自印度南部一个地区的定性研究
BMC Public Health. 2017 Aug 4;17(1):635. doi: 10.1186/s12889-017-4627-7.
3
Risk factors associated with MDR-TB at the onset of therapy among new cases registered with the RNTCP in Mumbai, India.印度孟买 RNTCP 登记的新病例中，治疗开始时与 MDR-TB 相关的危险因素。
Indian J Public Health. 2011 Jan-Mar;55(1):14-21. doi: 10.4103/0019-557X.82536.
Zotero 插件